

## **SUPPLEMENTARY MATERIAL**

### **Treatment Patterns and Clinical Characteristics of Systemic Lupus Erythematosus Patients With Musculoskeletal Symptoms: A Retrospective, Observational Study**

Natalia Bello,<sup>1</sup> Julie A. Birt,<sup>1</sup> Jennifer Workman,<sup>1</sup> Xian Zhou,<sup>2</sup> Jorge A. Ross-Terres,<sup>1</sup>  
Michelle Petri<sup>3</sup>

<sup>1</sup>Eli Lilly and Company, Indianapolis, USA; <sup>2</sup>Syneos Health, Morrisville, USA; <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, USA

#### **Corresponding author:**

Natalia Bello

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, IN 46285, U.S.A

+1 317. 741. 9838

[bello\\_natalia@lilly.com](mailto:bello_natalia@lilly.com)

**Table S1** Disease activity definitions and criteria.


SLE disease pattern	Definition	Criteria
<b>Chronically active</b>	Consistently active disease during a one-year period	<ul style="list-style-type: none"> <li>• SELENA-SLEDAI Arthritis &gt;0 at each visit during a one-year period</li> <li>or</li> <li>• LAI Arthralgia/ Arthritis <math>\geq 1</math> at each visit during a one-year period</li> </ul>
<b>Relapsing-remitting</b>	Active disease interspersed with periods of disease inactivity on one or more visits during a 1-year period	<p><i>Active disease</i></p> <ul style="list-style-type: none"> <li>• SELENA-SLEDAI &gt;0</li> <li>or</li> <li>• LAI Arthralgia/Arthritis <math>\geq 1</math> at least once during one-year period</li> </ul> <p><i>Inactive Disease</i></p> <ul style="list-style-type: none"> <li>• SELENA-SLEDAI Arthritis=0</li> <li>and</li> <li>• LAI Arthralgia/Arthritis=0</li> </ul>
<b>Long quiescence</b>	Inactive disease at all visits during a 1-year period.	<ul style="list-style-type: none"> <li>• SELENA-SLEDAI Arthritis=0</li> <li>and</li> <li>• LAI Arthralgia/ Arthritis=0</li> </ul>

LAI=Lupus Activity Index; SELENA-SLEDAI=Safety of Estrogens in Systemic Lupus

Erythematosus National Assessment- Systemic Lupus Erythematosus Disease Activity

Index; SLE=systemic lupus erythematosus.

**Supplementary Figure 1** Patient disposition from the Hopkins Lupus Cohort for patients included in the analysis of this study.




<sup>a</sup>Observation period was January 1, 2010 to December 31, 2019.

<sup>b</sup>History was before January 2010 or before the time entering the cohort if patient was enrolled after 2010.

<sup>c</sup>Presence of MSK symptoms was based on SELENA-SLEDAI arthritis or LAI arthralgia/arthritis VAS score  $\geq 1$  during the observation period and based on physician assessment for presence of arthralgia/arthritis during a patient's history for patients who entered the cohort after 2010. For patients who entered the cohort before 2010 MSK symptoms were defined using SELENA-SLEDAI, LAI, and physician assessment. LAI=Lupus Activity Index; MSK=musculoskeletal; N=number of patients; SELENA-SLEDAI=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLE=systemic lupus erythematosus; VAS=visual analog scale.

**Supplementary Figure 2** Proportion of time spent in each disease activity<sup>a</sup>.



<sup>a</sup>Patients with  $\geq 2$  visits during each year of observation were classified by yearly disease activity pattern.

CA=chronically active; LQ=long-quiescent; PY=person-years; RR=relapsing remitting.